It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Ovarian cancer (OC) is a disease with difficult early diagnosis and treatment and poor prognosis. OC data profiles were downloaded from The Cancer Genome Atlas. Eight key fatty acid metabolism-related long non-coding RNAs (lncRNAs) were finally screened for building a risk scoring model by univariate/ multifactor and least absolute shrinkage and selection operator (LASSO) Cox regression. To make this risk scoring model more applicable to clinical work, we established a nomogram containing the clinical characteristics of OC patients after confirming that the model has good reliability and validity and the ability to distinguish patient prognosis. To further explore how these key lncRNAs are involved in OC progression, we explored their relationship with LUAD immune signatures and tumor drug resistance. The structure shows that the risk scoring model established based on these 8 fatty acid metabolism-related lncRNAs has good reliability and validity and can better predict the prognosis of patients with different risks of OC, and LINC00861in these key RNAs may be a hub gene that affects the progression of OC and closely related to the sensitivity of current OC chemotherapy drugs. In addition, combined with immune signature analysis, we found that patients in the high-risk group are in a state of immunosuppression, and Tfh cells may play an important role in it. We innovatively established a prognostic prediction model with excellent reliability and validity from the perspective of OC fatty acid metabolism reprogramming and lncRNA regulation and found new molecular/cellular targets for future OC treatment.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Tianjin Medical University General Hospital, Department of Gynecology and Obstetrics, Heping, Tianjin, China (GRID:grid.412645.0) (ISNI:0000 0004 1757 9434); Tianjin Medical University General Hospital, Tianjin Key Laboratory of Female Reproductive Health and Eugenics, Tianjin, China (GRID:grid.412645.0) (ISNI:0000 0004 1757 9434); Jincheng People’s Hospital, Department of Gynecology, Jincheng, China (GRID:grid.415912.a) (ISNI:0000 0004 4903 149X)
2 Tianjin Medical University General Hospital, Department of Gynecology and Obstetrics, Heping, Tianjin, China (GRID:grid.412645.0) (ISNI:0000 0004 1757 9434); Tianjin Medical University General Hospital, Tianjin Key Laboratory of Female Reproductive Health and Eugenics, Tianjin, China (GRID:grid.412645.0) (ISNI:0000 0004 1757 9434)
3 Jincheng People’s Hospital, Department of Gynecology, Jincheng, China (GRID:grid.415912.a) (ISNI:0000 0004 4903 149X)
4 Jincheng People’s Hospital, Department of Pathology, Jincheng, China (GRID:grid.415912.a) (ISNI:0000 0004 4903 149X)